Professor Oliver Hanemann
Profiles

Professor Oliver Hanemann

Institute Director Translational and Stratified Medicine

Institute of Translational & Stratified Medicine (Plymouth University Peninsula Schools of Medicine and Dentistry)

Role

Director Institute of Translational and Stratified Medicine
Chair of Clinical Neurobiology
Plymouth University Peninsula School of Medicine and Dentistry
Neurology Consultant
Plymouth Hospital NHS Trust 

Qualifications

I trained at Medical School in Hamburg, Glasgow, Johns Hopkins and Harvard. After a DFG research fellowship in molecular neurobiology, in which I cloned the myelin protein PMP22 together with P Spreyer, I was neurology registrar at Medical School in Duesseldorf with Prof Freund. During that period I participated in resolving gene-defect and pathogenesis of the most frequent hereditary neuropathy CMT1A, became lecturer for Neurology and Neurobiology and honorary consultant at that department in 1998 and started work on benign glial tumours. From 2000 I was consultant incl. clinical lead and senior lecturer at the medical school in Ulm with Prof Ludolph continuing my work on benign glia tumours and neuropathies focussing more on motor neuropathies. During that time I was also trained as a medical geneticist. In 2005 I became chair of clinical neurobiology at the Peninsula medical school establishing clinical neurobiology research and administering different independent researcher groups. I successfully bridge basic and clinical sciences. I have been Associate Medical Director for R&D Plymouth Hospital NHS Trust and  and Academic lead department of Neurology PHNT

My new role at PU PSMD is Director of the Institute for Translational and Stratified Medicine where my remit is to champion research across traditional boundaries and focus on world-leading research.

Roles on external bodies

Nationally I am neurology lead in the Peninsula Neurooncology network, member NCRI brain tumour group and DeNDRON, (currently research director MND in the SW) member of scientific advisory boards (e.g. CTF, Lord Dowding Fund, Brain Research Trust), member of the council of the British Neuro-Oncology Society (BNOS). I am  reviewer for more than 17 international journals including Brain, Cancer Res, Oncogene and Human Mol Gen, and reviewer for a variety of granting agencies incl Wellcome, MRC, CR-UK and DFG.

Staff serving as external examiners

Involved in research SSU's, case units, lectures
External PhD examiner at: University of Exeter, University of Portsmouth, University Cardiff, Universit ät Jena, Universit ät Ulm

Research interests

My own focus is on neuromuscular disease esp. motor neuron disease and neurooncology. I supervised more than 15 PhD students quite a few finished with distinction and started a career in academia. Our current work on motor neuron disease is mainly clinical and includes genotype-phenotype analysis and clinical trials. In neurooncology we focus on cell biology studies to find and validate new therapeutic targets as there is a great medical need to find new treatments (summarized in Hanemann 2008, Ammoun and Hanemann 2011). Following our aim to work translational I also look after many patients with these diseases as a honorary consultant.

Research degrees awarded to supervised students

6 Phd's and 3 MD's finished successfully, 3 co-supervised successfully, 2 current

Grants & contracts

Over 2.1 Million £ previously excluding FEC. Currently Action Medical Research, Brain tumour charities, Dr Hadwen Trust and  Samantha Dickson Brain Tumour Trust

Key publications are highlighted

Journals
Articles
McGeachan AJ, Hobson EV, Al-Chalabi A, Stephenson J, Chandran S, Crawley F, Dick D, Donaghy C, Ellis CM & Gorrie G 2017 'A multicentre evaluation of oropharyngeal secretion management practices in amyotrophic lateral sclerosis' Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18, (1-2) 1-9 , DOI
Stepanova DS, Semenova G, Kuo Y-M, Andrews AJ, Ammoun S, Hanemann CO & Chernoff J 2017 'An essential role for the tumor suppressor Merlin in regulating fatty acid synthesis' Cancer Research Author Site , DOI PEARL
Provenzano L, Ryan Y, Hilton DA, Lyons-Rimmer J, Dave F, Maze EA, Adams CL, Rigby-Jones R, Ammoun S & Hanemann CO 2017 'Cellular prion protein (PrPC) in the development of Merlin-deficient tumours' Oncogene , DOI PEARL
Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M & Rudin CM 2017 'Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis' Molecular Cancer Therapeutics molcanther.0821.2016-molcanther.0821.2016 , DOI PEARL
Bassiri K, Ferluga S, Sharma V, Syed N, Adams CL, Lasonder E & Hanemann CO 2017 'Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target' EBioMedicine , DOI PEARL
Hilton DA, Shivane A, Kirk L, Bassiri K, Enki DG & Hanemann CO 2016 'Activation of multiple growth factor signalling pathways is frequent in meningiomas' Neuropathology 36, (3) 250-261 , DOI PEARL
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC & Evans DG 2016 'Current status and recommendations for biomarkers and biobanking in neurofibromatosis' Neurology 87, (7 Supplement 1) S40-S48 , DOI PEARL
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A & Salamon JM 2016 'Current whole-body MRI applications in the neurofibromatoses' Neurology 87, (7 Supplement 1) S31-S39 , DOI PEARL
Zeissler M-L, Eastwood J, McCorry K, Hanemann OC, Zajicek JP & Carroll CB 2016 'Delta-9-tetrahydrocannabinol protects against MPP<sup>+</sup> toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis' Oncotarget , DOI PEARL
McDermott CJ, Bradburn MJ, Maguire C, Cooper CL, Baird WO, Baxter SK, Cohen J, Cantrill H, Dixon S & Ackroyd R 2016 'DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis – a randomised controlled trial' Health Technology Assessment 20, (45) 1-186 , DOI PEARL
Walsh KS, Janusz J, Wolters PL, Martin S, Klein-Tasman BP, Toledo-Tamula MA, Thompson HL, Payne JM, Hardy KK & de Blank P 2016 'Neurocognitive outcomes in neurofibromatosis clinical trials' Neurology 87, (7 Supplement 1) S21-S30 , DOI PEARL
Hanemann CO, Wolters PL, Martin S, Merker VL, Tonsgard JH, Soloman SE, Baldwin A, Bergner AL, Walsh K & Thompson HL 2016 'Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials' Neurology 87, (7 Suppl 1) S4-S12 , DOI PEARL
Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE & Marcus CL 2016 'Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1' Neurology 87, (7 Supplement 1) S13-S20 , DOI PEARL
Zhou L, Lyons-Rimmer J, Ammoun S, Müller J, Lasonder E, Sharma V, Ercolano E, Hilton D, Taiwo I & Barczyk M 2016 'The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors' Oncogene 35, (26) 3443-3453 , DOI PEARL
Rauen KA, Huson SM, Burkitt-Wright E, Evans DG, Farschtschi S, Ferner RE, Gutmann DH, Hanemann CO, Kerr B & Legius E 2015 'Recent Developments in Neurofibromatoses and RASopathies: Management, Diagnosis and Current and Future Therapeutic Avenues' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 167, (1) 1-10 Author Site , DOI
2015 'Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial' The Lancet Neurology 14, (9) 883-892 , DOI PEARL
Ammoun S, Schmid MC, Zhou L, Hilton DA, Barczyk M & Hanemann CO 2015 'The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours' Mol Oncol 9, (1) 236-248 Author Site , DOI
Button RW, Lin F, Ercolano E, Vincent JH, Hu B, Hanemann CO & Luo S 2014 'Artesunate induces necrotic cell death in schwannoma cells' Cell Death Dis 5, Author Site , DOI PEARL
Ammoun S, Provenzano L, Zhou L, Barczyk M, Evans K, Hilton DA, Hafizi S & Hanemann CO 2014 'Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival' Oncogene 33, (3) 336-346 Author Site , DOI
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW & Dombi E 2014 'CTF Meeting 2012: Translation of the Basic Understanding of the Biology and Genetics of NF1, NF2, and Schwannomatosis Toward the Development of Effective Therapies' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 164, (3) 563-578 Author Site , DOI
Ammoun S, Provenzano L, Zhou L, Schmid MC & Hanemann CO 2014 'IDENTIFICATION AND TARGETING PATHWAYS INVOLVED IN THE DEVELOPMENT OF MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 5805-5805 Author Site
Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO & Hornigold R 2014 'Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2' JOURNAL OF NEUROLOGY 261, (5) 963-969 Author Site , DOI PEARL
Li W, Cooper J, Zhou L, Yang C, Erdjument-Bromage H, Zagzag D, Snuderl M, Ladanyi M, Hanemann CO & Zhou P 2014 'Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus' Cancer Cell 26, (1) 48-60 , DOI
Hilton DA & Hanemann CO 2014 'Schwannomas and their pathogenesis' Brain Pathol 24, (3) 205-220 Author Site , DOI
Hilton DA & Hanemann CO 2014 'Schwannomas and Their Pathogenesis' BRAIN PATHOLOGY 24, (3) 205-220 Author Site , DOI
Provenzano L, Ammoun S & Hanemann CO 2014 'THE ROLE OF CELLULAR PRION PROTEIN IN SCHWANNOMA AND OTHER MERLIN-DEFICIENT TUMOURS' ANTICANCER RESEARCH 34, (10) 6123-6123 Author Site
Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL & Widemann BC 2013 'Achieving consensus for clinical trials The REiNS International Collaboration' NEUROLOGY 81, (21) S1-S5 Author Site
Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL & Widemann BC 2013 'Achieving consensus for clinical trials: the REiNS International Collaboration' Neurology 81, (21 Suppl 1) S1-S5 Author Site , DOI
Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL & Plotkin SR 2013 'Conclusions and future directions for the REiNS International Collaboration' Neurology 81, (21 Suppl 1) S41-S44 Author Site , DOI
Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL & Plotkin SR 2013 'Conclusions and future directions for the REiNS International Collaboration' NEUROLOGY 81, (21) S41-S44 Author Site
Shivane A, Parkinson DB, Ammoun S & Hanemann CO 2013 'Expression of c-Jun and Sox-2 in human schwannomas and traumatic neuromas' HISTOPATHOLOGY 62, (4) 651-656 Author Site , DOI
Allen C, Counsell C, Farrin A, Al-Chalabi A, Dickie B, Leigh PN, Murphy CL, Payan C, Reynolds G & Shaw P 2013 'Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial' LANCET NEUROLOGY 12, (4) 339-345 Author Site , DOI
Doddrell RDS, Dun X-P, Shivane A, Feltri ML, Wrabetz L, Wegner M, Sock E, Hanemann CO & Parkinson DB 2013 'Loss of SOX10 function contributes to the phenotype of human Merlin-null schwannoma cells' Brain 136, (Pt 2) 549-563 Author Site , DOI PEARL
Hobson EV, McGeachan A, Al-Chalabi A, Chandran S, Crawley F, Dick D, Donaghy C, Ealing J, Ellis CM & Gorrie G 2013 'Management of sialorrhoea in motor neuron disease: A survey of current UK practice' AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION 14, (7-8) 521-527 Author Site , DOI
Rankin J, Short J, Turnpenny P, Castle B & Hanemann CO 2013 'Medulloblastoma in a Patient With the PTPN11 p.Thr468Met Mutation' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 161, (8) 2027-2029 Author Site , DOI
Schulz A, Baader SL, Niwa-Kawakita M, Jung MJ, Bauer R, Garcia C, Zoch A, Schacke S, Hagel C & Mautner V-F 2013 'Merlin isoform 2 in neurofibromatosis type 2–associated polyneuropathy' Nature Neuroscience 16, (4) 426-433 , DOI
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJM, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L & Papi L 2013 'Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria' AMERICAN JOURNAL OF MEDICAL GENETICS PART A 161A, (3) 405-416 Author Site , DOI
Zeissler ML, Eastwood J, Oliver Hanemann C, Zajicek J & Carroll C 2013 'Δ9–TETRAHYDROCANNABINOL IS PROTECTIVE THROUGH PPARγ DEPENDENT MITOCHONDRIAL BIOGENESIS IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' Journal of Neurology, Neurosurgery & Psychiatry 84, (11) e2.58-e2 , DOI PEARL
Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM & Jacob A 2012 'Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2' Am J Med Genet A 158A, (1) 24-41 Author Site , DOI
Ammoun S, Schmid MC, Zhou L, Ristic N, Ercolano E, Hilton DA, Perks CM & Hanemann CO 2012 'Insulin-like growth factor-binding protein-1 (IGFBP-1) regulates human schwannoma proliferation, adhesion and survival' Oncogene 31, (13) 1710-1722 Author Site , DOI
Zhou L & Hanemann CO 2012 'Merlin, a multi-suppressor from cell membrane to the nucleus' FEBS Lett 586, (10) 1403-1408 Author Site , DOI
Kalamarides M, Acosta MT, Babovic-Vuksanovic D, Carpen O, Cichowski K, Evans DG, Giancotti F, Hanemann CO, Ingram D & Lloyd AC 2012 'Neurofibromatosis 2011: a report of the Children's Tumor Foundation annual meeting' Acta Neuropathol 123, (3) 369-380 Author Site , DOI PEARL
Ammoun S, Schmid MC, Ristic N, Zhou L, Hilton D, Ercolano E, Carroll C & Hanemann CO 2012 'The role of insulin-like growth factors signaling in merlin-deficient human schwannomas' Glia 60, (11) 1721-1733 Author Site , DOI PEARL
Carroll CB, Zeissler M-L, Hanemann CO & Zajicek JP 2012 'Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease' Neuropathol Appl Neurobiol 38, (6) 535-547 Author Site , DOI
Zhang H, Hilton DA, Hanemann CO & Zajicek J 2011 'Cannabinoid Receptor and N-acyl Phosphatidylethanolamine Phospholipase D-Evidence for Altered Expression in Multiple Sclerosis' Brain Pathol 5, 544-557
Zhang H, Hilton DA, Hanemann CO & Zajicek J 2011 'Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis' Brain Pathol 21, (5) 544-557 Author Site , DOI
Carroll CB, Zeissler M-L, Chadborn N, Gibson K, Williams G, Zajicek JP, Morrison KE & Hanemann CO 2011 'Changes in iron-regulatory gene expression occur in human cell culture models of Parkinson's disease' Neurochem Int 59, (1) 73-80 Author Site , DOI PEARL
Ammoun S & Hanemann CO 2011 'Emerging therapeutic targets in schwannomas and other merlin-deficient tumors' Nat Rev Neurol 7, (7) 392-399 Author Site , DOI
Cooper J, Li W, Schiavon, Pepe-Caprio A, Zhou L, Ishii A, Hanemann CO, Long SB, Erdjument-Bromage H & Zhou P 2011 'Merlin/NF2 Functions Upstream of the Nuclear E3 Ubiquitin Ligase CRL4DCAF1 to Suppress Oncogenic Gene Expression' Scinece Siganlling 4,
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk MA & Hanemann CO 2011 'Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways' Neoplasia 13, (12) 1101-1112 Author Site
Ammoun S, Schmid MC, Triner J, Manley P & Hanemann CO 2011 'Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2' Neuro Oncol 13, (7) 759-766 Author Site , DOI
Al-Chalabi A, Shaw PJ, Young CA, Morrison KE, Murphy C, Thornhill M, Kelly J, Steen IN, Leigh PN & UKMND-LiCALS 2011 'Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31]' BMC Neurol 11, Author Site , DOI
George JS, Harikrishnan S, Ali I, Baresi R & Hanemann CO 2010 'Acquired rippling muscle disease in association with myasthenia gravis' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 81, (1) 125-126 Author Site , DOI
Carroll CB, Zeissler ML, Stone V, Hanemann CO & Zajicek JP 2010 'Cannabinoids Are Neuroprotective in a Human Cell Culture Model of Parkinson's Disease' MOVEMENT DISORDERS 25, S621-S621 Author Site PEARL
Carroll CB, Zeissler ML, Chadborn N, Gibson K, Williams GJ, Morrison KE, Zajicek JP & Hanemann CO 2010 'Changes in Iron-Regulatory Gene Expression Occur in Human Cell Culture Models of PD' MOVEMENT DISORDERS 25, S628-S628 Author Site PEARL
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 2010 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol 12, (8) 834-843 Author Site , DOI
Ammoun S, Cunliffe CH, Allen J, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 2010 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro Oncol. 8, (12) 834-43
Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, Ishii R, Giovannini M, Hanemann CO & Long SB 2010 'Merlin/NF2 Suppresses Tumorigenesis by Inhibiting the E3 Ubiquitin Ligase CRL4DCAF1 in the Nucleus' Cell 140, (4) 477-490 , DOI
Ammoun S, Ristic N, Matthies C, Hilton DA & Hanemann CO 2010 'Targeting ERK1/2 activation and proliferation in human primary schwannoma cells with MEK1/2 inhibitor AZD6244' Neurobiol Dis 37, (1) 141-146 Author Site , DOI
Imam I, Ball S, Wright D & Hanemann CO 2010 'The epidemiology of motor neurone disease in two counties in the southwest of England' Journal of Neurology Publisher Site
Imam I, Edwards S & Hanemann CO 2009 'Acquired neuromyotonia following upper respiratory tract infection: a case report' Cases J 2, Author Site , DOI PEARL
Hilton DA, Ristic N & Hanemann CO 2009 'Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ' Histopathology 55, (6) 744-749 Author Site , DOI
Flaiz C, Ammoun S, Biebl A & Hanemann CO 2009 'Altered adhesive structures and their relation to RhoGTPase activation in merlin-deficient Schwannoma' Brain Pathol 19, (1) 27-38 Author Site , DOI
Imam I, Edwards S & Hanemann CO 2009 'Aquired neuromyotonia following upper respiratory tract infection' Case J 2, 7952-7952 PEARL
Flaiz C, Chernoff J, Ammoun S, Peterson JR & Hanemann CO 2009 'PAK kinase regulates Rac GTPase and is a potential target in human schwannomas' Exp Neurol 218, (1) 137-144 Author Site
Ammoun S, Flaiz C, Ristic N, Schuldt J & Hanemann CO 2008 'Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma' Cancer Res 68, (13) 5236-5245 Author Site , DOI
Widmer M, Hanemann CO & Zajicek J 2008 'High concentrations of cannabinoids activate apoptosis in human U373MG glioma cells' J Neurosci Res 86, (14) 3212-3220 Author Site , DOI
Flaiz C, Utermark T, Parkinson DB, Poetsch A & Hanemann CO 2008 'Impaired intercellular adhesion and immature adherens junctions in merlin-deficient human primary schwannoma cells' Glia 56, (5) 506-515 Author Site , DOI
Hanemann CO 2008 'Magic but treatable? Tumours due to loss of Merlin' BRAIN 131, 606-615 Author Site , DOI
Flaiz C & Hanemann CO 2007 'Actin-rich protrusions and non-localised GTPase activation in merlin-deficient schwannomas' NEURON GLIA BIOLOGY 2, S123-S123 Author Site
Flaiz C, Kaempchen K, Matthies C & Hanemann CO 2007 'Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannornas' Journal of Neuropathology and Experimental Neurology 66, (7) 608-616
Flaiz C, Kaempchen K, Matthies C & Hanemann CO 2007 'Actin-rich protrusions and nonlocalized GTPase activation in Merlin-deficient schwannornas' JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 66, (7) 608-616 Author Site , DOI
Gdynia HJ, Sperfeld AD & Hanemann CO 2007 'Central core myopathy. A juvenile and adult disease' Nervenarzt 78, (4) 387-+
Gdynia HJ, Sperfeld A-D & Hanemann CO 2007 'Central core myopathy. A juvenile and adult disease' NERVENARZT 78, (4) 387-+ Author Site , DOI
Titley G 2007 'Electronic signatures for copyright in the UK: a solution to the "holy grail" of document delivery' Interlending and Document Supply 35, (1) 15-20 , DOI PEARL
Flaiz C & Hanemann OC 2007 'Like to move it? Actin-rich protrusions, migration and adhesion in schwannoma, a benign tumour of the nervous system' Neuropathology and Applied Neurobiology 33, (2) 259-259
Hanemann CO, Hayward C & Hilton DA 2007 'Neurofibromatosis type 1 with involvement of the enteric nerves' J Neurol Neurosurg Psychiatry 78, (10) 1163-1164 Author Site , DOI
Hanemann CO, Hayward C & Hilton DA 2007 'Neurofibromatosis type 1 with involvement of the enteric nerves' Journal of Neurology Neurosurgery and Psychiatry 78, (10) 1163-1164
Hanemann CO 2007 'Pathobiology of schwannomas' Journal of Neurology Neurosurgery and Psychiatry 78, (2)
Hanemann O, Diebold R & Kaufmann D 2007 'Role of NF2 Haploinsufficiency in NF2-associated Polyneuropathy' Brain Pathology 0, (0) 371-376 , DOI
Ammoun S & Hanemann O 2007 'Strong and long-lasting activation of ERK in human schwannoma cells' Neuropathology and Applied Neurobiology 33, (2) 258-259
Gronholm M, Muranen T, Toby GG, Utermark T, Hanemann CO, Golemis EA & Carpen O 2006 'A functional association between merlin and HEI10, a cell cycle regulator' ONCOGENE 25, (32) 4389-4398 Author Site , DOI
Gdynia H-J, Sperfeld A-D, Knirsch U, Homberg V, Rosenbohm A, Müller-Höcker J, Ludolph AC & Hanemann CO 2006 'Benign symmetric lipomatosis with axonal neuropathy and abnormalities in specific mitochondrial tRNA regions' Eur J Med Res 11, (12) 545-546 Author Site
Hanemann CO, Bartelt-Kirbach B, Diebold R, Kaempchen K, Langmesser S & Utermark T 2006 'Differential gene expression between human schwannoma and control Schwann cells' NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY 32, (6) 605-614 Author Site , DOI
Hanemann CO 2006 'Insights from the development of Schwann cell tumours' Neuromuscular Disorders 16, S105-S106
Hanemann CO & Evans DG 2006 'News on the genetics, epidemiology, medical care and translational research of Schwannomas' JOURNAL OF NEUROLOGY 253, (12) 1533-1541 Author Site , DOI
Titley G 2006 'Practical Issues: Copyright for Clinical Teachers' The Clinical Teacher 3, (1) 60-64 Publisher Site
Hanemann CO, Kaempchen KE, Kaufmann D & Krause BJ 2005 'Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2' Archives of Neurology 62, (4) 674-675
Hanemann CO, Kaempchen KE, Kaufmann D & Krause BJ 2005 'Fludeoxyglucose F 18 positron emission tomography and computed tomography of a giant retroperitoneal schwannoma occurring in a patient with neurofibromatosis type 2' ARCHIVES OF NEUROLOGY 62, (4) 674-675 Author Site , DOI
Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Krause BJ, Sedlmeier R, Meyer T, Hanemann CO & Stumm G 2005 'Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD' Annals of Neurology 58, (5) 777-780
Muench C, Rosenbohm A, Sperfeld AD, Uttner I, Meyer T, Hanemann CO, Stumm G & Ludolph AC 2005 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)' EUROPEAN JOURNAL OF NEUROLOGY 12, 27-27 Author Site
Muench C, Rosenbohm A, Sperfeld AD, Uttner I, Meyer T, Hanemann CO, Stumm G & Ludolph AC 2005 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD)' European Journal of Neurology 12, 27-27
Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Meyer T, Hanemann CO, Stumm G & Ludolph AC 2005 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis and frontotemporal dementia' Journal of Neurology 252, 18-18
Münch C, Rosenbohm A, Sperfeld A-D, Uttner I, Reske S, Krause BJ, Sedlmeier R, Meyer T, Hanemann CO & Stumm G 2005 'Heterozygous R1101K mutation of theDCTN1 gene in a family with ALS and FTD' Annals of Neurology 58, (5) 777-780 , DOI
Sperfeld AD, Hanemann CO, Ludolph AC & Kassubek J 2005 'Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy' NEUROLOGY 64, (4) 753-754 Author Site
Sperfeld AD, Hanemann CO, Ludolph AC & Kassubek J 2005 'Laryngospasm: An underdiagnosed symptom of X-linked spinobulbar muscular atrophy' Neurology 64, (4) 753-754
Hanemann CO & Ludolph AC 2005 'Motor protein diseases of the nervous system' AMYOTROPHIC LATERAL SCLEROSIS AND OTHER MOTOR NEURON DISORDERS 6, (4) 197-201 Author Site , DOI
Hanemann CO & Ludolph AC 2005 'Motor protein diseases of the nervous system' Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 6, (4) 197-201
Sperfeld AD, Bretschneider V, Flaith L, Unrath A, Hanemann CO, Ludolph AC & Kassubek J 2005 'MR-Pathologic comparison of the upper spinal cord in different motor neuron diseases' EUROPEAN NEUROLOGY 53, (2) 74-77 Author Site , DOI
Sperfeld AD, Bretschneider V, Flaith L, Unrath A, Hanemann CO, Ludolph AC & Kassubek J 2005 'MR-Pathologic comparison of the upper spinal cord in different motor neuron diseases' European Neurology 53, (2) 74-77
Utermark T, Schubert SJA & Hanemann CO 2005 'Rearrangements of the intermediate filament GFAP in primary human schwannoma cells' NEUROBIOLOGY OF DISEASE 19, (1-2) 1-9 Author Site , DOI
Utermark T, Schubert SJA & Hanemann CO 2005 'Rearrangements of the intermediate filament GFAP in primary human schwannoma cells' Neurobiology of Disease 19, (1-2) 1-9
Utermark T, Kaempchen K, Antoniadis G & Hanemann CO 2005 'Reduced apoptosis rates in human schwannomas' BRAIN PATHOLOGY 15, (1) 17-22 Author Site
Utermark T, Kaempchen K, Antoniadis G & Hanemann CO 2005 'Reduced apoptosis rates in human schwannomas' Brain Pathology 15, (1) 17-22
Diebold R, Bartelt-Kirbach B, Evans DG, Kaufmann D & Hanemann CO 2005 'Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction' JOURNAL OF MOLECULAR DIAGNOSTICS 7, (1) 97-104 Author Site , DOI
Diebold R, Bartelt-Kirbach B, Evans DG, Kaufmann D & Hanemann CO 2005 'Sensitive detection of deletions of one or more exons in the neurofibromatosis type 2 (NF2) gene by multiplexed gene dosage polymerase chain reaction' Journal of Molecular Diagnostics 7, (1) 97-104
Hirokowa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V & Maruta H 2005 'Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228' CANCER BIOLOGY & THERAPY 4, (4) 379-381 Author Site
Hirokowa Y, Nakajima H, Hanemann CO, Kurtz A, Frahm S, Mautner V & Maruta H 2005 'Signal therapy of NF1-deficient tumor xenograft in mice by the anti-PAK1 drug FK228' Cancer Biology & Therapy 4, (4) 379-381
Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J & Maruta H 2004 'A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor' CANCER JOURNAL 10, (1) 20-26 Author Site , DOI
Hirokawa Y, Tikoo A, Huynh J, Utermark T, Hanemann CO, Giovannini M, Xiao GH, Testa JR, Wood J & Maruta H 2004 'A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor' Cancer Journal 10, (1) 20-26
Sperfeld AD, Kassubek J, Crosby AH, Winner B, Ludolph AC, Uttner I & Hanemann CO 2004 'Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time' JOURNAL OF NEUROLOGY 251, (10) 1285-1287 Author Site , DOI
Sperfeld AD, Kassubek J, Crosby AH, Winner B, Ludolph AC, Uttner I & Hanemann CO 2004 'Complicated hereditary spastic paraplegia with thin corpus callosum: Variation of phenotypic expression over time' Journal of Neurology 251, (10) 1285-1287
Walter MC, Petersen JA, Stucka R, Fischer D, Schroder R, Vorgerd M, Schroers A, Schreiber H, Hanemann CO & Knirsch U 2004 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' Journal of Medical Genetics 41, (4)
Walter MC, Petersen JA, Stucka R, Fischer D, Schroder R, Vorgerd M, Schroers A, Schreiber H, Hanemann CO & Knirsch U 2004 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' Journal of Neurology 251, 15-15
Walter MC 2004 'FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients' Journal of Medical Genetics 41, (4) e50-e50 , DOI
Munch C, Sperfeld AD, Meyer T, Prudlo J, Hanemann CO, Stumm G & Ludolph AC 2004 'Point mutations of the p150 subunit of dynactin (DCTN1) and absence of mutations in the cytoplasmic dynein heavy chain (DNCHC1) gene in amyotrophic lateral sclerosis' Journal of Neurology 251, 33-33
Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO & Stumm G 2004 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS' NEUROLOGY 63, (4) 724-726 Author Site
Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO & Stumm G 2004 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS' Neurology 63, (4) 724-726
Muench C, Sedlmeier R, Meyer T, Homberg V, Sperfeld AD, Kurt A, Prudlo J, Peraus G, Hanemann CO & Stumm G 2004 'Point mutations of the p150 subunit of dynactin (DCTN1) gene in amyotrophic lateral sclerosis' Annals of Neurology 56, S30-S30
Zuchner S, Sperfeld AD, Senderek J, Sellhaus B, Hanemann CO & Schroder JM 2003 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' BRAIN 126, 920-927 Author Site , DOI
Zuchner S, Sperfeld AD, Senderek J, Sellhaus B, Hanemann CO & Schroder JM 2003 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' Brain 126, 920-927
Hanemann CO & Ludolph AC 2003 'ALS/MND meeting of the European ALS/MND group Reisensburg Castle 30 January – 1 February 2003' Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders 4, (2) 121-122 , DOI
Utermark T, Kaempchen K & Hanemann CO 2003 'Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins' Brain Pathology 13, (3) 352-363
Utermark T, Kaempchen K & Hanemann CO 2003 'Pathological adhesion of primary human schwannoma cells is dependent on altered expression of integrins' BRAIN PATHOLOGY 13, (3) 352-363 Author Site
Utermark T, Alekov A, Lerche H, Abramowski V, Giovannini M & Hanemann CO 2003 'Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells' CANCER 97, (8) 1955-1962 Author Site , DOI
Utermark T, Alekov A, Lerche H, Abramowski V, Giovannini M & Hanemann CO 2003 'Quinidine impairs proliferation of neurofibromatosis type 2-deficient human malignant mesothelioma cells' Cancer 97, (8) 1955-1962
Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T & Tenenbaum L 2003 'Tetracycline-inducible transgene expression mediated by a single AAV vector' Gene Therapy 10, (1) 84-94
Chtarto A, Bender HU, Hanemann CO, Kemp T, Lehtonen E, Levivier M, Brotchi J, Velu T & Tenenbaum L 2003 'Tetracycline-inducible transgene expression mediated by a single AAV vector' GENE THERAPY 10, (1) 84-94 Author Site , DOI
Hanemann CO, Bergmann C, Senderek J, Zerres K & Sperfeld AD 2003 'Transient, recurrent, white matter lesions in x-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation' Archives of Neurology 60, (4) 605-609
Hanemann CO, Bergmann C, Senderek J, Zerres K & Sperfeld AD 2003 'Transient, recurrent, white matter lesions in x-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation' ARCHIVES OF NEUROLOGY 60, (4) 605-609 Author Site , DOI
Hanemann O, Kaempchen K, Mielke K & Utermark T 2003 'Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells' Human Molecular Genetics 12, (11) 1211-1221 , DOI
Kaempchen K, Mielke K, Utermark T, Langmesser S & Hanemann CO 2003 'Upregulation of the Rac1/JNK signaling pathway in primary human schwannoma cells' Human Molecular Genetics 12, (11) 1211-1221
Hanemann CO, Gabreels-Festen AAWM & De Jonghe P 2002 'Axon damage in CMT due to mutation in myelin protein P0 (vol 11, pg 753, 2001)' Neuromuscular Disorders 12, (4) 432-432
Hanemann CO, Gabreels-Festen AAWM & De Jonghe P 2002 'Axon damage in CMT due to mutation in myelin protein P0 (vol 11, pg 753, 2001)' NEUROMUSCULAR DISORDERS 12, (4) 432-432 Author Site , DOI
Utermark T, McLaughlin K & Hanemann CO 2002 'Enhanced adhesion of Schwannoma cells is dependent on an increased expression of the integrin alpha 6, beta 1 and beta 4 chains in vitro' GLIA S31-S31 Author Site
Utermark T, McLaughlin K & Hanemann CO 2002 'Enhanced adhesion of Schwannoma cells is dependent on an increased expression of the integrin alpha 6, beta 1 and beta 4 chains in vitro' Glia S31-S31
Hanemann CO & Ludolph AC 2002 'Hereditary motor neuropathies and motor neuron diseases: which is which' Amyotroph Lateral Scler Other Motor Neuron Disord 3, (4) 186-189 Author Site
Zuchner S, Sperfeld A, Hanemann CO & Schroder JM 2002 'Novel point mutation of the ABC1 gene in Tangier disease with severe syringomyelia-like phenotype and unique endoneurial sclerosis' Journal of the Neurological Sciences 199,
Hanemann CO, Sperfeld AD, Hein C, Schroder JM & Ludolph AC 2002 'Occurrence and characterisation of peripheral nerve involvement in neurofibromatosis type 2' Journal of the Neurological Sciences 199,
Hanemann O, Hein C, Schroder M & Sperfeld A 2002 'Occurrence and characterization of  peripheral nerve involvement in neurofibromatosis type 2' Brain 125, (5) 996-1004 , DOI
Sperfeld AD, Hein C, Schroder JM, Ludolph AC & Hanemann CO 2002 'Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2' Brain 125, 996-1004
Hanemann CO & Gabreels-Festen AAWM 2002 'Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies' CURRENT OPINION IN NEUROLOGY 15, (5) 611-615 Author Site , DOI
Hanemann CO & Gabreels-Festen AAWM 2002 'Secondary axon atrophy and neurological dysfunction in demyelinating neuropathies' Current Opinion in Neurology 15, (5) 611-615
Schulze KMM, Hanemann CO, Muller HW & Hanenberg H 2002 'Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis' Human Molecular Genetics 11, (1) 69-76
Hanemann O, Hanenberg H, Muller H & Schulze K 2002 'Transduction of wild-type merlin into human schwannoma cells decreases schwannoma cell growth and induces apoptosis' Human Molecular Genetics 11, (1) 69-76 , DOI
Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Haussler J, Ludolph AC & Hanemann CO 2002 'X-linked bulbospinal neuronopathy - Kennedy disease' Archives of Neurology 59, (12) 1921-1926
Sperfeld AD, Karitzky J, Brummer D, Schreiber H, Haussler J, Ludolph AC & Hanemann CO 2002 'X-linked bulbospinal neuronopathy - Kennedy disease' ARCHIVES OF NEUROLOGY 59, (12) 1921-1926 Author Site , DOI
Hanemann CO, Sperfeld AD, Karitzky J, Schreiber H, Brummer D, Haussler J & Ludolph AC 2002 'X-linked bulbospinal neuronopathy Kennedy: Presence of known and unknown clinical features and electrophysiological investigation in 34 cases' Journal of the Neurological Sciences 199,
Hanemann CO, Gabreels-Festen AAWM & De Jonghe P 2001 'Axon damage in CMT due to mutation in myelin protein P0' NEUROMUSCULAR DISORDERS 11, (8) 753-756 Author Site , DOI
Hanemann CO, Gabreels-Festen AAWM & De Jonghe P 2001 'Axon damage in CMT due to mutation in myelin protein P0' Neuromuscular Disorders 11, (8) 753-756
Hanemann CO 2001 'Hereditary demyelinating neuropathies: from gene to disease' NEUROGENETICS 3, (2) 53-57 Author Site , DOI
Hanemann CO 2001 'Hereditary demyelinating neuropathies: from gene to disease' Neurogenetics 3, (2) 53-57
Kaufmann D, Muller R, Bartelt B, Wolf M, Kunzi-Rapp K, Hanemann CO, Fahsold R, Hein C, Vogel W & Assum G 2001 'Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene' American Journal of Human Genetics 69, (6) 1395-1400
Kaufmann D, Müller R, Bartelt B, Wolf M, Kunzi-Rapp K, Hanemann CO, Fahsold R, Hein C, Vogel W & Assum G 2001 'Spinal Neurofibromatosis without Café-au-Lait Macules in Two Families with Null Mutations of the NF1 Gene' The American Journal of Human Genetics 69, (6) 1395-1400 , DOI
Rosenbaum C, Kamleiter M, Grafe P, Kluwe L, Mautner VF, Muller HW & Hanemann CO 2000 'Enhanced proliferation and potassium conductance of schwann cells isolated from NF2 schwannomas can be reduced by quinidine' NEUROBIOLOGY OF DISEASE 7, (4) 483-491 Author Site , DOI
Rosenbaum T, Rosenbaum C, Winner U, Muller HW, Lenard HG & Hanemann CO 2000 'Long-term culture and characterization of human neurofibroma-derived Schwann cells' JOURNAL OF NEUROSCIENCE RESEARCH 61, (5) 524-532 Author Site , DOI
Hanemann CO, D'Urso D, Gabreëls-Festen AAWM & Müller HW 2000 'Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot–Marie–Tooth type 1A' Brain 123, (5) 1001-1006 , DOI
Tenenbaum L, Hamdane M, Pouzet M, Avalosse B, Stathopoulos A, Jurysta F, Rosenbaum C, Hanemann CO, Levivier M & Velu T 1999 'Cellular contaminants of adeno-associated virus vector stocks can enhance transduction' GENE THERAPY 6, (6) 1045-1053 Author Site , DOI
Hanemann CO & Neuen-Jacob E 1999 'Muscle injury in Guillain-Barré syndrome: a case report' Journal of Neurology 246, (12) 1207-1208 , DOI
Mayer C, Kamleiter M, Sanchez-Brandelik R, Rosenbaum C, Kluwe L, Hanemann CO & Grafe P 1999 'Neuroligand-mediated calcium signaling in cultured human schwannoma cells' JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM 4, (2) 99-105 Author Site
Hanemann CO, Rosenbaum C, Kupfer S, Wosch S, Stoegbauer F & Muller HW 1998 'Improved culture methods to expand schwann cells with altered growth behaviour from CMT1A patients' GLIA 23, (2) 89-98 Author Site , DOI
Rosenbaum C, Kluwe L, Mautner VF, Friedrich RE, Muller HW & Hanemann CO 1998 'Isolation and characterization of Schwann cells from neurofibromatosis type 2 patients' NEUROBIOLOGY OF DISEASE 5, (1) 55-64 Author Site , DOI
Stoll G, Gabreels-Festen AAWM, Jander S, Muller HW & Hanemann CO 1998 'Major histocompatibility complex class II expression and macrophage responses in genetically proven Charcot-Marie-Tooth type 1 and hereditary neuropathy with liability to pressure palsies' MUSCLE & NERVE 21, (11) 1419-1427 Author Site , DOI
Hanemann CO & Muller HW 1998 'Pathogenesis of Charcot-Marie-Tooth IA (CMTIA) neuropathy' TRENDS IN NEUROSCIENCES 21, (7) 282-286 Author Site , DOI
Kappos L, European Study Group on Interferon ß-1b in Secondary Progressive MS & Hanemann CO 1998 'Placebo-controlled multicentre randomised trial of interferon ß-1b in treatment of secondary progressive multiple sclerosis' The Lancet 352, (9139) 1491-1497 , DOI
Kamleiter M, Hanemann CO, Kluwe L, Rosenbaum C, Wosch S, Mautner VF, Muller HW & Grafe P 1998 'Voltage-dependent membrane currents of cultured human neurofibromatosis type 2 Schwann cells' GLIA 24, (3) 313-322 Author Site , DOI
Müller HW, Suter U, Van Broeckhoven C, Hanemann CO, Nelis E, Timmerman V, Sancho S, Barrio L, Bolhuis P & Dermietzel R 1997 'Advances in Charcot-Marie-Tooth disease research: cellular function of CMT-related proteins, transgenic animal models, and pathomechanisms. The European CMT Consortium' Neurobiol Dis 4, (3-4) 215-220 Author Site
Korinthenberg R, Sauer M, Ketelsen UP, Hanemann CO, Stoll G, Graf M, Baborie A, Volk B, Wirth B & RudnikSchoneborn S 1997 'Congenital axonal neuropathy caused by deletions in the spinal muscular atrophy region' ANNALS OF NEUROLOGY 42, (3) 364-368 Author Site , DOI
Hermanns S, Wunderlich G, Rosenbaum C, Hanemann CO, Muller HW & Stichel CC 1997 'Lack of immune responses to immediate or delayed implanted allogeneic and xenogeneic Schwann cell suspensions' GLIA 21, (3) 299-314 Author Site
Muller HW, DUrso D, Zoidl G & Hanemann CO 1997 'Peripheral myelin protein 22kD (PMP22): Structure, function and role in demyelinating hereditary neuropathies' JOURNAL OF NEUROCHEMISTRY 69, S94-S94 Author Site
Hanemann CO, GabreelsFesten AAWM, Stoll G & Muller HW 1997 'Schwann cell differentiation in Charcot-Marie-Tooth disease type 1A (CMT1A): normal number of myelinating Schwann cells in young CMT1A patients and neural cell adhesion molecule expression in onion bulbs' ACTA NEUROPATHOLOGICA 94, (4) 310-315 Author Site
Hanemann CO, Hefter H, Schlaug G, Seitz RJ, Freund HJ & Benecke R 1996 'Characterization of basal ganglia dysfunction in Leber 'plus' disease' JOURNAL OF NEUROLOGY 243, (3) 297-300 Author Site , DOI
Hanemann CO, GabreelsFesten AAWM, Muller HW & Stoll G 1996 'Low affinity NGF receptor expression in CMT1A nerve biopsies of different disease stages' BRAIN 119, 1461-1469 Author Site , DOI
HANEMANN CO, STOLL G & MULLER HW 1995 'PMP22 EXPRESSION IN CMT1A NEUROPATHY' ANNALS OF NEUROLOGY 37, (1) 136-136 Author Site , DOI
HANEMANN CO, STOLL G, DURSO D, FRICKE W, MARTIN JJ, VAN BROECKHOVEN C, MANCARDI GL, BARTKE I & MULLER HW 1994 'PERIPHERAL MYELIN PROTEIN-22 EXPRESSION IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A SURAL NERVE BIOPSIES' JOURNAL OF NEUROSCIENCE RESEARCH 37, (5) 654-659 Author Site , DOI
HANEMANN CO, KLEINSCHMIDT A, REIFENBERGER G, FREUND HJ & SEITZ RJ 1993 'BALO CONCENTRIC SCLEROSIS FOLLOWED BY MRI AND POSITRON EMISSION TOMOGRAPHY' NEURORADIOLOGY 35, (8) 578-580 Author Site
Hanemann CO, Kleinschmidt A, Reifenberger G, Freund HJ & Seitz RJ 1993 'Balo's concentric sclerosis followed by MRI and positron emission tomography' Neuroradiology 35, (8) 578-580 Author Site
Hanemann CO, Kuhn G, Lie A, Gillen C, Bosse F, Spreyer P & Müller HW 1993 'Expression of decorin mRNA in the nervous system of rat' Journal of Histochemistry & Cytochemistry 41, (9) 1383-1391 , DOI
HANEMANN CO, MULLER HW & FREUND HJ 1992 'MOLECULAR UNDERSTANDING AND DNA TEST FOR CHARCOT-MARIE-TOOTH DISEASE IN SIGHT' AKTUELLE NEUROLOGIE 19, (6) 182-184 Author Site , DOI
MATSUNAMI N, SMITH B, BALLARD L, LENSCH MW, ROBERTSON M, ALBERTSEN H, HANEMANN CO, MULLER HW, BIRD TD & WHITE R 1992 'PERIPHERAL MYELIN PROTEIN-22 GENE MAPS IN THE DUPLICATION IN CHROMOSOME-17P11.2 ASSOCIATED WITH CHARCOT-MARIE-TOOTH-1A' NATURE GENETICS 1, (3) 176-179 Author Site , DOI
TIMMERMAN V, NELIS E, VANHUL W, NIEUWENHUIJSEN BW, CHEN KL, WANG S, OTHMAN KB, CULLEN B, LEACH RJ & HANEMANN CO 1992 'THE PERIPHERAL MYELIN PROTEIN GENE PMP-22 IS CONTAINED WITHIN THE CHARCOT-MARIE-TOOTH DISEASE TYPE-1A DUPLICATION' NATURE GENETICS 1, (3) 171-175 Author Site , DOI
SPREYER P, KUHN G, HANEMANN CO, GILLEN C, SCHAAL H, KUHN R, LEMKE G & MULLER HW 1991 'AXON-REGULATED EXPRESSION OF A SCHWANN-CELL TRANSCRIPT THAT IS HOMOLOGOUS TO A GROWTH ARREST-SPECIFIC GENE' EMBO JOURNAL 10, (12) 3661-3668 Author Site
Bullock R, Hanemann CO, Murray L & Teasdale GM 1990 'Recurrent hematomas following craniotomy for traumatic intracranial mass' J Neurosurg 72, (1) 9-14 Author Site , DOI
Ammoun S, Cunliffe CH, Allen JC, Chiriboga L, Giancotti FG, Zagzag D, Hanemann CO & Karajannis MA 0 'ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma' Neuro-oncology Publisher Site , DOI PEARL
Letters
Sher I, Hanemann CO, Karplus PA & Bretscher A 2012 'The tumor suppressor merlin controls growth in its open state, and phosphorylation converts it to a less-active more-closed state' Dev Cell 22, (4) 703-705 Author Site , DOI
Carroll C, Krolikowski K, Mukonoweshuro W, Jones J & Hanemann CO 2010 'Unilateral cerebral hemisphere oedema as a peri-ictal phenomenon' J Neurol 257, (12) 2094-2096 Author Site , DOI
Chapters
Hanemann CO & Ammoun S 2010 'Receptor tyrosine kinases in human schwannoma' Angiogenesis &amp; Therapeutic Targets In Cancer 90-98 , DOI
Conference Papers
Hanemann CO, Ferluga S, Dunn J, Bassiri K, Sharma V & Lasonder E 2016 'ANALYSIS OF THE PROTEOM AND PHOSHOPROTEOM OF MENINGIOMAS' 68-68
Dunn J, Ferluga S, Sharma V, Hilton DA, Bassiri K & Hanemann CO 2016 'Identification of novel molecular targets in stratified meningiomas using a proteomic approach' 20-20
Hilton DA, Shivane A, Kirk L, Bassiri K & Hanemann CO 2015 'GROWTH FACTOR SIGNALLING PATHWAYS IN MENINGIOMAS IS COMMON AND PARTLY DEPENDS ON SUBTYPE ALLOWING FOR STRATIFICATION' 14-14
Hanemann CO, Hilton D, Shivane A & Turner L 2014 'ACTIVATION OF MULTIPLE GROWTH FACTOR SIGNALLING PATHWAYS IS FREQUENT IN MENINGIOMAS'
Sittampalam M & Hanemann O 2014 'CLINICAL MORVAN'S AND ELECTRICAL MND' , DOI
Hilton D, Shivane A, Kirk L, Ammoun S & Hanemann CO 2014 'Growth factor signaling pathway activation in meningiomas' 101-101
Hilton DA, Shivane A, Turner L, Ammoun S & Hanemann O 2013 'Activation of multiple signalling pathways in meningiomas is unrelated to NF2 gene status' 35-35
Schulz A, Baader S, Niwa-Kawakita M, Bauer R, Jung J, Zoch A, Schacke S, Hagel C, Mautner V & Hanemann O 2013 'THE ROLE OF MERLIN ISOFORM 2 IN NEUROFIBROMATOSIS TYPE 2-ASSOCIATED POLYNEUROPATHY' S104-S104
Barczyk M, Zhou L, Avent N & Hanemann O 2013 'Tumour suppressor merlin regulates thrombospondin 1 signalling via CD47' 381-381
Salter E, Zeissler ML, Alexander SPH, Hanemann CO, Zajicek JP & Carroll CB 2012 'ENDOCANNABINOID TOXICITY IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' , DOI
Shivane A, Ammoun S, Parkinson DB & Hanemann CO 2012 'EXPRESSION OF C-JUN & SOX-2 IN HUMAN SCHWANNOMAS AND TRAUMATIC NEUROMAS' 9-10
Zeissler M, Hanemann CO, Zajicek JP & Carroll CB 2012 'FAAH INHIBITION IS PROTECTIVE IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' , DOI
Zeissler M, Carroll CB, Hanemann CO & Zajieck JP 2012 'INVESTIGATING THE NEUROPROTECTIVE PROPERTIES OF Delta 9-THC IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' , DOI
Zhou L, Ercolano E, Ammoun S, Schmid MC, Barczyk M & Hanemann CO 2012 'MERLIN DEFICIENT HUMAN TUMOURS SHOW LOSS OF CONTACT INHIBITION, ACTIVATION OF WNT/beta-CATENIN SIGNALING LINKED TO THE PDGFR/SRC AND RAC/PAK PATHWAYS' 5-6
Barczyk M, Zhou L, Avent N & Hanemann O 2012 'Tumour Suppressor Merlin Regulates Thrombospondin 1 Signalling Via CD47' 162-162
Shivane A, Hilton DA & Hanemann CO 2011 'Acquired rippling muscle disease-report of two cases' 29-29
Ammoun S, Zhou L, Barczyk M, Hilton D, Hafizi S & Hanemann CO 2011 'GAS6/AXL-FAMILY RECEPTORS IN SCHWANNOMA PATHOLOGICAL PROLIFERATION, ADHESION AND SURVIVAL' 1-1
Carroll C, Zajicek JP, Hanemann CO, Stone V & Zeissler M 2010 'CANNABINOIDS ARE NEUROPROTECTIVE IN A HUMAN CELL CULTURE MODEL OF PARKINSON'S DISEASE' E60-E60 , DOI
Carroll C, Williams GJ, Chadborn NH, Hanemann CO, Zajicek JP, Morrison KE, Gibson K & Zeissler M 2010 'CHANGES IN IRON-REGULATORY GENE EXPRESSION OCCUR IN HUMAN CELL CULTURE MODELS OF PARKINSON'S DISEASE' E29-E29 , DOI
Hanemann CO, Ammoun S, Schmid MC, Ristic N, Ercolano E & Zhou L 2010 'IGF/IGFBP SIGNALING IN MERLIN-DEFICIENT TUMORS' 22-22
Schmid MC, Zhou L, Ammoun S & Hanemann CO 2010 'Targeting focal adhesion kinase (FAK) in primary human schwannoma' 42-42 , DOI
Krolikowski K, Hanemann O & Jones J 2010 'TREACHEROUS TRIANGLE OF TUMOUR, SEIZURE AND STROKE' E39-E39 , DOI
Zhang H, Hanemann O, Widmer M, Hosking R, Chadborn N, Zajicek J & Hilton DA 2009 'Cannabinoid receptors expression in multiple sclerosis' 17-17
Carroll CB, Chadborn N, Hanemann O & Zajicek J 2009 'CANNABINOIDS ARE NEUROPROTECTIVE IN A CELL CULTURE MODEL OF PARKINSON'S DISEASE' , DOI
Hanemann CO & Ammoun S 2009 'MERLIN'S TUMOURS: FROM BENCH TO BEDSIDE' , DOI
Doddrell R, Hanemann CO & Parkinson DB 2009 'REGULATION OF CELL DIFFERENTIATION IN MERLIN NULL TUMOURS' S170-S170
George JS, Harikrishnan S, Ali I, Baresi R & Hanemann CO 2009 'RIPPLING MUSCLE DISEASE IN ASSOCIATION WITH MYASTHENIA GRAVIS' , DOI
Imam I, Ball S, Wright D, Hanemann O & Zajicek J 2009 'THE EPIDEMIOLOGY OF MOTOR NEURONE DISEASE IN TWO COUNTIES IN THE SOUTH WEST OF ENGLAND' , DOI
Flaiz C, Hanemann CO & Medimond 2007 'Non-localised Rac1 and Cdc42 activation and protrusive activity in schwannoma, a benign tumour of the nervous system' 107-112
Flaiz C & Hanemann CO 2007 'Non-localised Rac1 and Cdc42 activation and protrusive activity in schwannoma, a benign tumour of the nervous system' Proceedings of the Viii European Meeting on Glial Cells in Health and Disease 107-112
Hanemann CO 2007 'Pathobiology of schwannomas' 214-214
Ammoun S & Hanemann O 2007 'Strong and long-lasting activation of ERK in human schwannoma cells' 258-259
Munch C, Rosenbohm A, Sperfeld A, Meyer T, Hanemann O & Ludolph A 2006 'Heterozygous R1101K mutation of the DCTN1 gene in a family with frontotemporal dementia and amyotrophic lateral sclerosis' S64-S64
Hanemann CO 2006 'Insights from the development of Schwann cell tumours' S105-S106
Munch C, Rosenbohm A, Sperfeld AD, Uttner I, Reske S, Meyer T, Hanemann CO, Stumm G & Ludolph AC 2005 'Heterozygous R1101K mutation of the DCTN1 gene in a family with amyotrophic lateral sclerosis and frontotemporal dementia' 18-18
Walter MC, Petersen JA, Stucka R, Fischer D, Schroder R, Vorgerd M, Schroers A, Schreiber H, Hanemann CO & Knirsch U 2004 'FKRP (826C > A) frequently causes limb-girdle muscular dystrophy in German patients' 15-15
Munch C, Sperfeld AD, Meyer T, Prudlo J, Hanemann CO, Stumm G & Ludolph AC 2004 'Point mutations of the p150 subunit of dynactin (DCTN1) and absence of mutations in the cytoplasmic dynein heavy chain (DNCHC1) gene in amyotrophic lateral sclerosis' 33-33
Hanemann CO & Ludolph AC 2003 'ALS/MND meeting of the European ALS/MND group Reisenburg Castle 30 January - 1 February 2003' 121-122 , DOI
Zuchner S, Sperfeld AD, Senderek J, Sellhaus B, Hanemann CO & Schroder JM 2002 'A novel nonsense mutation in the ABC1 gene causes a severe syringomyelia-like phenotype of Tangier disease' 577-578
Hanemann CO, Sperfeld AD, Hein C, Schroder JM & Ludolph AC 2002 'Occurrence and characterisation of peripheral nerve involvement in neurofibromatosis type 2' S60-S60
Hanemann CO, Sperfeld AD, Karitzky J, Schreiber H, Brummer D, Haussler J & Ludolph AC 2002 'X-linked bulbospinal neuronopathy Kennedy: Presence of known and unknown clinical features and electrophysiological investigation in 34 cases' S76-S77